BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 27845387)

  • 1. Adenoviral vectors encoding CRISPR/Cas9 multiplexes rescue dystrophin synthesis in unselected populations of DMD muscle cells.
    Maggio I; Liu J; Janssen JM; Chen X; Gonçalves MA
    Sci Rep; 2016 Nov; 6():37051. PubMed ID: 27845387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-Capacity Adenoviral Vectors Permit Robust and Versatile Testing of
    Brescia M; Janssen JM; Liu J; Gonçalves MAFV
    Cells; 2020 Apr; 9(4):. PubMed ID: 32252479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selection-free gene repair after adenoviral vector transduction of designer nucleases: rescue of dystrophin synthesis in DMD muscle cell populations.
    Maggio I; Stefanucci L; Janssen JM; Liu J; Chen X; Mouly V; Gonçalves MA
    Nucleic Acids Res; 2016 Feb; 44(3):1449-70. PubMed ID: 26762977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The emerging role of viral vectors as vehicles for DMD gene editing.
    Maggio I; Chen X; Gonçalves MA
    Genome Med; 2016 May; 8(1):59. PubMed ID: 27215286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo genome editing in mouse restores dystrophin expression in Duchenne muscular dystrophy patient muscle fibers.
    Chen M; Shi H; Gou S; Wang X; Li L; Jin Q; Wu H; Zhang H; Li Y; Wang L; Li H; Lin J; Guo W; Jiang Z; Yang X; Xu A; Zhu Y; Zhang C; Lai L; Li X
    Genome Med; 2021 Apr; 13(1):57. PubMed ID: 33845891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic Applications of CRISPR/Cas for Duchenne Muscular Dystrophy.
    Wong TWY; Cohn RD
    Curr Gene Ther; 2017; 17(4):301-308. PubMed ID: 29173172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Single CRISPR-Cas9 Deletion Strategy that Targets the Majority of DMD Patients Restores Dystrophin Function in hiPSC-Derived Muscle Cells.
    Young CS; Hicks MR; Ermolova NV; Nakano H; Jan M; Younesi S; Karumbayaram S; Kumagai-Cresse C; Wang D; Zack JA; Kohn DB; Nakano A; Nelson SF; Miceli MC; Spencer MJ; Pyle AD
    Cell Stem Cell; 2016 Apr; 18(4):533-40. PubMed ID: 26877224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The AAV-mediated and RNA-guided CRISPR/Cas9 system for gene therapy of DMD and BMD.
    Wang JZ; Wu P; Shi ZM; Xu YL; Liu ZJ
    Brain Dev; 2017 Aug; 39(7):547-556. PubMed ID: 28390761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional Rescue of Dystrophin Deficiency in Mice Caused by Frameshift Mutations Using Campylobacter jejuni Cas9.
    Koo T; Lu-Nguyen NB; Malerba A; Kim E; Kim D; Cappellari O; Cho HY; Dickson G; Popplewell L; Kim JS
    Mol Ther; 2018 Jun; 26(6):1529-1538. PubMed ID: 29730196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Restoration of Dystrophin Protein Expression by Exon Skipping Utilizing CRISPR-Cas9 in Myoblasts Derived from DMD Patient iPS Cells.
    Ifuku M; Iwabuchi KA; Tanaka M; Lung MSY; Hotta A
    Methods Mol Biol; 2018; 1828():191-217. PubMed ID: 30171543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Creation of DMD Muscle Cell Model Using CRISPR-Cas9 Genome Editing to Test the Efficacy of Antisense-Mediated Exon Skipping.
    Maruyama R; Yokota T
    Methods Mol Biol; 2018; 1828():165-171. PubMed ID: 30171541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel human muscle cell model of Duchenne muscular dystrophy created by CRISPR/Cas9 and evaluation of antisense-mediated exon skipping.
    Shimo T; Hosoki K; Nakatsuji Y; Yokota T; Obika S
    J Hum Genet; 2018 Mar; 63(3):365-375. PubMed ID: 29339778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Full-length dystrophin restoration via targeted exon integration by AAV-CRISPR in a humanized mouse model of Duchenne muscular dystrophy.
    Pickar-Oliver A; Gough V; Bohning JD; Liu S; Robinson-Hamm JN; Daniels H; Majoros WH; Devlin G; Asokan A; Gersbach CA
    Mol Ther; 2021 Nov; 29(11):3243-3257. PubMed ID: 34509668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiplex CRISPR/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy.
    Ousterout DG; Kabadi AM; Thakore PI; Majoros WH; Reddy TE; Gersbach CA
    Nat Commun; 2015 Feb; 6():6244. PubMed ID: 25692716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Creation of a Novel Humanized Dystrophic Mouse Model of Duchenne Muscular Dystrophy and Application of a CRISPR/Cas9 Gene Editing Therapy.
    Young CS; Mokhonova E; Quinonez M; Pyle AD; Spencer MJ
    J Neuromuscul Dis; 2017; 4(2):139-145. PubMed ID: 28505980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy.
    Bengtsson NE; Hall JK; Odom GL; Phelps MP; Andrus CR; Hawkins RD; Hauschka SD; Chamberlain JR; Chamberlain JS
    Nat Commun; 2017 Feb; 8():14454. PubMed ID: 28195574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of CRISPR-Mediated Systems in the Study of Duchenne Muscular Dystrophy.
    Cai A; Kong X
    Hum Gene Ther Methods; 2019 Jun; 30(3):71-80. PubMed ID: 31062609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correction of Three Prominent Mutations in Mouse and Human Models of Duchenne Muscular Dystrophy by Single-Cut Genome Editing.
    Min YL; Chemello F; Li H; Rodriguez-Caycedo C; Sanchez-Ortiz E; Mireault AA; McAnally JR; Shelton JM; Zhang Y; Bassel-Duby R; Olson EN
    Mol Ther; 2020 Sep; 28(9):2044-2055. PubMed ID: 32892813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Production of Duchenne muscular dystrophy cellular model using CRISPR-Cas9 exon deletion strategy.
    Alizadeh F; Abraghan YJ; Farrokhi S; Yousefi Y; Mirahmadi Y; Eslahi A; Mojarrad M
    Mol Cell Biochem; 2024 May; 479(5):1027-1040. PubMed ID: 37289342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced CRISPR-Cas9 correction of Duchenne muscular dystrophy in mice by a self-complementary AAV delivery system.
    Zhang Y; Li H; Min YL; Sanchez-Ortiz E; Huang J; Mireault AA; Shelton JM; Kim J; Mammen PPA; Bassel-Duby R; Olson EN
    Sci Adv; 2020 Feb; 6(8):eaay6812. PubMed ID: 32128412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.